渤健公司于2026年美国皮肤病学会年会上宣布,其研发的利替利单抗在针对皮肤红斑狼疮的第二项二期临床试验中再次获得积极数据。试验结果表明,该疗法能显著降低患者的皮肤疾病活动度。
渤健公司于2026年美国皮肤病学会年会上宣布,其研发的利替利单抗在针对皮肤红斑狼疮的第二项二期临床试验中再次获得积极数据。试验结果表明,该疗法能显著降低患者的皮肤疾病活动度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.